

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

Cotellic (cobimetinib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Cotellic (cobimetinib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Cotellic (cobimetinib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of unresectable or metastatic Melanoma (Label, NCCN 1, 2A); **AND**
 - A. Individual has BRAF V600E or V600K mutation (or BRAF V600 activating mutation), with test results confirmed; **AND**
 - B. Individual is using in combination with vemurafenib;

OR

- II. Individual has a diagnosis of Central Nervous System cancer (NCCN 2A); **AND**
 - A. Individual is using in combination with vemurafenib; **AND**
 - B. Individual is using as adjuvant therapy for primary CNS cancer; **AND**
 - C. Individual has BRAF V600E mutation with test result confirmed.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 8, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2020 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 8, 2020.
 - a. Central Nervous System Cancers. V2.2020. Revised April 20, 2020.
 - b. Cutaneous Melanoma. V3.2020. Revised May 18, 2020.

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.